Success Metrics

Clinical Success Rate
78.8%

Based on 227 completed trials

Completion Rate
79%(227/288)
Active Trials
24(7%)
Results Posted
48%(108 trials)
Terminated
61(17%)

Phase Distribution

Ph phase_2
134
37%
Ph phase_3
51
14%
Ph phase_4
64
18%
Ph phase_1
74
20%
Ph early_phase_1
6
2%
Ph not_applicable
25
7%

Phase Distribution

80

Early Stage

134

Mid Stage

115

Late Stage

Phase Distribution354 total trials
Early Phase 1First-in-human
6(1.7%)
Phase 1Safety & dosage
74(20.9%)
Phase 2Efficacy & side effects
134(37.9%)
Phase 3Large-scale testing
51(14.4%)
Phase 4Post-market surveillance
64(18.1%)
N/ANon-phased studies
25(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.7%

227 of 304 finished

Non-Completion Rate

25.3%

77 ended early

Currently Active

24

trials recruiting

Total Trials

365

all time

Status Distribution
Active(27)
Completed(227)
Terminated(77)
Other(34)

Detailed Status

Completed227
Terminated61
unknown32
Recruiting16
Withdrawn16
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
365
Active
24
Success Rate
78.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.7%)
Phase 174 (20.9%)
Phase 2134 (37.9%)
Phase 351 (14.4%)
Phase 464 (18.1%)
N/A25 (7.1%)

Trials by Status

recruiting164%
withdrawn164%
unknown329%
completed22762%
active_not_recruiting82%
suspended21%
terminated6117%
not_yet_recruiting31%

Recent Activity

Clinical Trials (365)

Showing 20 of 365 trialsScroll for more
NCT06245109Phase 4

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

Recruiting
NCT07559682Phase 1

Efficacy of Selective COX-2 Inhibitors in Relieving Orthodontic Pain

Active Not Recruiting
NCT02993029Not Applicable

99Tc-MDP Treatment for Knee Osteoarthritis

Recruiting
NCT06997068Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Recruiting
NCT06699966Phase 4

Stony Brook Medicine Anti-Inflammatory Trial

Not Yet Recruiting
NCT04765644Phase 4

Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment

Completed
NCT03818932Phase 2

Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction

Completed
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting
NCT05731726Phase 2

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Recruiting
NCT02574728Phase 2

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Active Not Recruiting
NCT03974932Phase 3

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

Completed
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting
NCT04469530Phase 2

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Recruiting
NCT04093323Phase 2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Terminated
NCT01356290Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting
NCT05488847Phase 4

Opioid-Free Pain Protocol After Shoulder Arthroplasty

Active Not Recruiting
NCT01881048Early Phase 1

Window of Opportunity Study Targeting the Inflammatory Milieu

Completed
NCT07174570Phase 2

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Recruiting
NCT06076837Phase 1

The Seven Trial: Exploiting the Unfolded Protein Response

Active Not Recruiting
NCT05077332Phase 2

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
365